What is the National vaccine Advisory Committee NVAC?

National Vaccine Advisory Committee (NVAC) Official websites use,gov A,gov website belongs to an official government organization in the United States. Secure,gov websites use HTTPS A lock ( A locked padlock ) or https:// means you’ve safely connected to the,gov website. Share sensitive information only on official, secure websites. : National Vaccine Advisory Committee (NVAC)

How much is Robert Kennedy Jr worth?

Robert F. Kennedy Jr. Net Worth

What are the requirements for Ncvia?

Vaccine Information Statements – The NCVIA requires that all health care providers who administer vaccines against diphtheria, tetanus, pertussis, polio, measles, mumps, rubella, hepatitis B, Haemophilus influenzae type b and varicella must provide a Vaccine Information Statement (VIS) to the vaccine recipient, their parent or legal guardian prior to each dose.A VIS must be given with every vaccination, including each dose in a multi-dose series.

What is the Childhood vaccine Injury Act of 1986?

Vaccine Injury Compensation Program The National Childhood Vaccine Injury Act of 1986, as amended, created a unique mechanism for compensating persons injured by vaccinations. The National Vaccine Injury Compensation Program (the “VICP” or the “Program”) (42 U.S.C.

1. §§ 300aa-10 et seq.) is an alternative to traditional products liability and medical malpractice litigation for persons injured by their receipt of one or more of the standard childhood vaccines.
2. The VICP is designed to encourage vaccination by providing a streamlined system for compensation in rare instances where an injury results from vaccination.

Over the past 35 years, the VICP has succeeded in providing a less adversarial, less expensive, and less time-consuming system of recovery than the traditional tort system that governs medical malpractice, personal injury, and product liability cases.

Almost 9,500 people have been paid in excess of $4.5 billion since the Program’s 1988 inception. Individuals who believe they have been injured by a covered vaccine can file a claim against the Secretary of the Department of Health and Human Services (HHS) in the U.S. Court of Federal Claims seeking compensation from the Vaccine Trust Fund.

Civil Division, Torts Branch attorneys in the Office of Vaccine Litigation defend HHS against claims filed under the VICP, and ensure that fair compensation is awarded in every case meeting the eligibility criteria. Eligible claimants can recover compensation for vaccine injury-related medical and rehabilitative expenses, for pain and suffering, and lost earnings.

• By protecting the Vaccine Trust Fund against claims by those who have not suffered a vaccine-related injury, the Office of Vaccine Litigation helps to preserve the Fund for future eligible claimants.
• Claimants may also recover reasonable attorney’s fees and costs, and the Program also permits attorney fee awards to be made when a claim is otherwise denied, as long as it was filed in good faith, and with a reasonable basis.

Vaccines covered under the Program include those that protect against diphtheria, tetanus, pertussis (whooping cough), measles, mumps, rubella (German measles), polio, hepatitis A, hepatitis B, varicella (chickenpox), Hemophilus influenzae type b, rotavirus, pneumococcal conjugate, trivalent influenza (seasonal flu), meningococcal conjugate and human papillomavirus.

A significant, positive result of the Program is that costly litigation against drug manufacturers and health care professionals who administer vaccines has substantially decreased. Although an individual who is dissatisfied with the Court’s final judgment has the option to file a lawsuit in State or Federal court, few lawsuits have been filed since the Program began.

The supply of vaccines in the U.S. has stabilized, and the development of new vaccines has markedly increased. For more information about the Vaccine Injury Compensation Program, please visit the HHS, : Vaccine Injury Compensation Program

Who has been nominated to the Board of the Global Alliance for Vaccines and Immunization from India?

– Posted On: 29 DEC 2020 5:16PM by PIB Delhi Dr. Harsh Vardhan, Union Minister of Health and Family Welfare has been nominated by the Global Alliance for Vaccines and Immunisation (GAVI) as a member on the GAVI Board. Dr. Harsh Vardhan will be representing the South East Area Regional Office (SEARO)/ Western Pacific Regional Office (WPRO) constituency on the GAVI Board. The seat is currently held by Mr. MyintHtwe of Myanmar. Dr. Harsh Vardhan will be representing India from 1 st January 2021 until 31 st December 2023.

• The Board normally meets twice a year in June and November/ Decemberand holds an annual retreat, normally in March or April.
• All these meetings arenormally attended in person.
• The GAVIBoard is responsible for strategic direction and policy-making, oversees the operations of the Vaccine Alliance and monitors programme implementation.

With membership drawn from a range of partner organisations, as well as experts from the private sector, the Board provides a forum for balanced strategic decision making, innovation and partner collaboration. GAVI, the Vaccine Alliance as part of its mission to save lives, reduce poverty and protect the world against the threat of epidemics, has helped vaccinate more than 822 million children in the world’s poorest countries, preventing more than 14 million future deaths.

Which organizations publish immunization schedules?

Who Sets the Immunization Schedule? As part of its mission to promote health and prevent disease, CDC publishes written recommendations for vaccinating US children and adults. These recommendations are set to protect infants, children, adolescents, and adults against vaccine-preventable diseases.

1. Medical and public health experts review available data on newly licensed and existing vaccines.
2. These experts, who include vaccine experts, scientists, doctors, and public health professionals, form the Advisory Committee on Immunization Practices (ACIP).
3. ACIP meets 3 times each year to discuss vaccine recommendations.

They consider

How safe and effective the vaccine is when given at a specific age The severity of the disease the vaccine prevents How many people get the disease if there is no vaccine How well the vaccine helps the body produce immunity to the disease

The final vaccine recommendations include the

Number of doses of each vaccine, Timing between each dose, Age when infants and children should receive the vaccine, and Precautions and contraindications (who should not receive the vaccine).

CDC sets the immunization schedules based on ACIP’s recommendations. The childhood and adolescent schedules are also approved by the American Academy of Pediatrics (AAP), the American Academy of Family Physicians (AAFP), and the American College of Obstetricians and Gynecologists.

How much money did Jackie Onassis inherit from Aristotle?

Although the bulk of his estate went to his daughter after his death in 1975, Jacqueline inherited a sum variously estimated at $20 million to $26 million.

Who is the richest Kennedy family member?

The Kennedy family remains one of the most storied political dynasties in US history. Descending from humble Irish roots in County Wexford, the Kennedy family -and those who have married into it – has gone on to enjoy great success both politically and financially in the US.

1. Forbes reported that as of 2015, the Kennedy family, accounting for some 30 individuals, was valued at $1.2 billion.
2. For comparison, in 2018, the Walton family behind the American department store Wal-Mart, was valued at $152 billion making them the richest family in America,) In 2017, The International Business Times reported that the Kennedy family’s “lasting wealth is attributed to the fact that Joseph P.

Kennedy, who made his fortune in insider trading, tucked the money into dozens of trusts. Those trusts are managed by Joseph P. Kennedy Enterprises, the investment firm headed by Chris Kennedy.” Presently, the Kennedy family with the highest net worth who is still alive is considered to be Caroline Kennedy, with a staggering estimated net worth of $250 million.

How did Kennedy make his money?

Business career – Kennedy set his sights on a business career upon his graduation from Harvard. During his mid to late 20s, he made a large fortune as an active commodity and stock investor; he then reinvested much of this into film studios, real estate, and shipping.

Though he never built a significant business from scratch, Kennedy’s timing as both buyer and seller was nonetheless excellent. Various criminals, such as Frank Costello, have boasted they worked with Kennedy in mysterious bootlegging operations during Prohibition, Although his father was in the whisky importation business, scholars dismiss the claims.

The most recent and most thorough biographer David Nasaw asserts that no credible evidence has been found to link Kennedy to bootlegging activities. When Fortune magazine published its first list of the richest people in the United States in 1957, it placed Kennedy in the $200–400 million group.

What are the eight details that must be documented when a vaccination is given?

Standard 9: Providers use accurate and complete recording procedures. – This standard specifies the orderly approach that should be taken to ensure accurate record-keeping, so that needed vaccinations will not be missed and unnecessary vaccinations will not be given.

Immunization providers are required by law to record what vaccine was given, the date the vaccine was given (month, day, year), the name of the manufacturer of the vaccine, the lot number, the signature and title of the person who gave the vaccine, and the address where the vaccine was given. NVAC believes that in addition, the parent or guardian should be given a permanent record to keep and carry to office visits for updates.

If this record is lost, a replacement with complete immunization data should be provided. Providers should verify vaccination histories from previous providers whenever possible, and if the provider of an immunization is not the primary care physician, a report of vaccines given should be sent to the primary care provider.

What is the National vaccine Safety Surveillance Program?

About VAERS – VAERS is the nation’s early warning system that monitors the safety of vaccines after they are authorized or licensed for use by the U.S. Food and Drug Administration (FDA). VAERS is part of the larger vaccine safety system in the United States that helps make sure vaccines are safe.

• The system is co-managed by CDC and FDA.
• VAERS accepts and analyzes reports of possible health problems—also called “adverse events”—after vaccination.
• As an early warning system, VAERS cannot prove that a vaccine caused a problem.
• Specifically, a report to VAERS does not mean that a vaccine caused an adverse event,

But VAERS can give CDC and FDA important information. If it looks as though a vaccine might be causing a problem, FDA and CDC will investigate further and take action if needed. Anyone can submit a report to VAERS — healthcare professionals, vaccine manufacturers, and the general public.

VAERS is a national vaccine safety surveillance program that helps to detect unusual or unexpected reporting patterns of adverse events for vaccines. VAERS accepts reports from anyone, including patients, family members, healthcare providers and vaccine manufacturers. VAERS is not designed to determine if a vaccine caused or contributed to an adverse event. A report to VAERS does not mean the vaccine caused the event. VAERS is a passive surveillance system, meaning it relies on people sending in reports of their experiences after vaccination. Healthcare providers and vaccine manufacturers are required by law to report certain events after vaccination. If VAERS detects a pattern of adverse events following vaccination, other vaccine safety monitoring systems conduct follow up studies.

What are the requirements for vaccinology?

Entry requirements –

A bachelor’s degree of at least 4 years’ duration from Wits or another university or a bachelor’s degree followed by an honours degree. Working experience (minimum 1 year) in the field of infectious diseases, immunology, vaccinology/ immunisation or research in a relevant field. Please note that fulfilment of the application requirements does not guarantee a place. South African Qualifications Authority (SAQA) Certificate of Evaluation for foreign qualifications ( www.saqa.org.za )

What childhood vaccine left a scar on your arm?

What to Know About the Smallpox Vaccination Scar Medically Reviewed by on May 26, 2022 Before the was destroyed in the early 1980s, many people received the smallpox vaccine. As a result, if you’re in your 40s or older, you likely have a permanent scar from an older version of the smallpox vaccine on your upper left arm.

1. Although it’s a harmless skin injury, you might be curious about its causes and potential treatments for removal.
2. Here’s all you need to know about the smallpox vaccination scar.
3. Before the smallpox vaccine existed, variolation – direct exposure to smallpox sores – was the usual immunization method.
4. Material from smallpox sores was inhaled or rubbed into the skin.

It was hoped that this would cause a smallpox infection that could be controlled and give a person immunity in the future. The smallpox vaccination came out in the late 1700s to replace this practice. Between the late 1960s and the early 1980s, the World Health Organization (WHO) began a worldwide immunization effort to eradicate – or completely destroy – the virus.

If you’re from a younger generation, you probably don’t have a smallpox vaccination scar. Typically, only people over 40 years of age might have the dime-sized dent on their upper left arm. This mark is a distinctive sign that you received the vaccine at some point. ‌ There haven’t been any smallpox cases since 1977.

It’s unlikely that you’ll need a smallpox vaccination unless you’re in the military or work on smallpox vaccination research. To give the smallpox vaccine, doctors use a technique called the puncture method. It requires a different type of needle from the usual vaccination needle.

1. Dip the two-pronged needle into the vaccine suspension.
2. Shallowly but vigorously prick the skin with the needle 15 times.
3. Observe the changes of the skin injury over the next few days.

Exposure to the live virus from the vaccine can leave a sore and itchy bump behind that later blisters before becoming a permanent scar. What causes the smallpox vaccination scar? The vaccination technique isn’t to blame for the scar. The smallpox vaccine holds a live virus.

1. It creates a controlled infection that forces your to defend your body against the virus.
2. The exposure to the virus tends to leave a sore and itchy bump behind.
3. This bump later becomes a larger blister that leaves a permanent scar as it dries up.
4. What happens if the vaccination spot doesn’t get infected? If your vaccination spot doesn’t develop a bump that fills up with pus during the first week after application, the immunization process was unsuccessful.

In this unlikely situation, doctors recommend revaccinating. Your skin’s reaction to a second dose will usually be milder and heal faster. Your smallpox vaccination spot must heal on its own for the immunization process to be successful, but certain measures can prevent the virus from spreading while the skin lesion is still fresh.

• Cover the area with gauze and breathable bandages.
• Make sure the cover doesn’t allow liquid to escape.
• Change the gauze and bandages every third day or whenever it gets wet.
• Wash hands with the proper technique after touching the wound.
• Don’t let others touch the blister or the liquid it makes.
• Do laundry separately and don’t share clothes, towels, or sheets.
• Machine-wash infected clothes with warm water and detergent.
• Put used bandages in a separate plastic bag before throwing away.

Possible smallpox vaccination complications. The most common complication happens when you accidentally transfer the virus from the pus-filled blister to a different body part. The areas most likely to be affected in this way are your mouth, eyes, nose, and genital area.

• In rare cases, this problem can cause — the clear layer covering the colored part of the eye.
• ‌ A lesser-known complication is the appearance of aggressive skin tumors on the smallpox vaccination scar over time due to trauma.
• Experts call this condition dermatofibrosarcoma protuberans (DFSP).
• This problem is extremely rare: There have been only five documented cases in the U.S.

since the 1940s. ‌ People who have – an inflammatory skin condition – can get an infection called eczema vaccinatum when exposed to the live virus in the vaccine. Although uncommon, this issue is potentially serious and can cause severe discomfort. If you’re vulnerable to this infection, you should avoid the smallpox vaccine and skin-to-skin contact for 30 days with anyone who receives it.

• Because the smallpox virus is closely related to the monkeypox virus, the smallpox vaccine can give you some protection against monkeypox.
• Studies show that the vaccine is about 85% effective at preventing monkeypox.
• But the immunity doesn’t last forever.
• Research shows the first dose only protects you for about 3 to 5 years.

After that, the immunity it gives you against both diseases start to dip. If you have a scar on your arm from the first generation of smallpox vaccines and you’re exposed to monkeypox, you might have a milder illness. So, if you’re exposed to monkeypox but haven’t had the smallpox vaccine within the last 3 years, the CDC recommends getting revaccinated as soon as possible.

Two smallpox vaccines are currently licensed in the U.S. to prevent smallpox: ACAM2000 and JYNNEOS (which is also known by the brand names Imvamune and Imvanex). JYNNEOS is also specifically licensed to prevent monkeypox. ACAM2000 is put into the skin by pricking the skin surface and can leave a scar at the injection site.

JYNNEOS is given as a non-replicating live virus, and no sore develops. The smallpox vaccination scar usually isn’t a threat to your health. If you have one and how it looks bothers you, you can have a scar removal procedure to get rid of it. Your doctor may treat it like a – a type of raised scar. © 2021 WebMD, LLC. All rights reserved. : What to Know About the Smallpox Vaccination Scar

What is the scar on my arm from childhood vaccine?

Smallpox vs. BCG Vaccine Scar – Like the smallpox vaccine, the Bacille Calmette-Guérin (BCG) vaccine,which offers protection against tuberculosis (TB) disease, is not given routinely in the United States. It’s still often administered to infants and children in countries where TB disease is more common.

Both the smallpox vaccine and the tuberculosis vaccine cause a blister to fill with pus, crust over, and form a scab within a few weeks. People who received the BCG vaccine in the past often have a permanent scar in the area where they received the injection. However, the BCG vaccine scar is typically raised in the middle and may have more rounded edges.

The smallpox vaccine is usually depressed, or lower than the skin around it. The edges of the scar may be more irregular.

What vaccine was given to children in the 1960s?

Vaccination Assistance Act – Before 1962, no formal nationwide immunization program existed. Vaccines were administered in private practices and local health departments and paid for out of pocket or provided by using state or local government funds with some support from federal Maternal and Child Health Block Grant funds. In 1962, the Vaccination Assistance Act (Section 317 of the Public Health Service Act) was passed to “achieve as quickly as possible the protection of the population, especially of all preschool children.through intensive immunization activity over a limited period of time.” The initial intention was to allow CDC to support mass, intensive vaccination campaigns. However, the Vaccination Assistance Act also established a mechanism to provide ongoing financial support to state or local health departments and direct support “in lieu of cash.” The direct support included provision of vaccines and of CDC Public Health Advisors to assist in managing the programs. Section 317 has been reauthorized repeatedly since 1962 and remains one of the most important means of supporting health department immunization activities with federal funds ( 1 ). At the initiation of the 317 funding program in 1963, the only vaccines routinely recommended for children were diphtheria and tetanus toxoids and pertussis vaccine (DTP), polio, and smallpox. Measles vaccine was licensed in 1963, and in 1966, a goal was set to eradicate measles from the United States ( 2 ). Measles incidence declined dramatically after large vaccination campaigns, but transmission was not interrupted. The licensure of rubella vaccine in 1969 led to mass campaigns to immunize children to avert an anticipated repeat of the tragic epidemic of 1964-65, which resulted in the births of approximately 20,000 infants with congenital rubella syndrome. The rubella campaigns diverted attention and funding from measles, resulting in a resurgence of measles. Federal funding for Section 317 declined during the early to mid-1970s. Immunization coverage fell, and disease increased. In April 1977, a Childhood Immunization Initiative was announced with two goals: attainment of immunization levels of 90% in the nation’s children by October 1979 and establishment of a permanent system to provide comprehensive immunization services to the 3 million children born each year in the United States. Increased funding was provided through Section 317, and a major effort was made to review vaccination records of school children and vaccinate those in need. State and local public health personnel reviewed >28 million records during a 2-year period. In addition, state and local authorities enacted and enforced school immunization requirements. By 1980, all 50 states had such laws, and since 1981, immunization levels of students entering schools have been ≥95%. Thus, the first target of the initiative was met. Achieving the second target would take considerably longer. A major weakness of Section 317 in its early years was the assumption that state and local health departments could provide the infrastructure necessary to actually administer vaccines. Consequently, Section 317 funds were not authorized for paying salaries of persons who administered the vaccines. The result was that local health departments became increasingly unable to provide the services necessary to ensure that preschool-aged children received vaccines on time, and private sector clinicians were not filling this need, particularly in low-income communities. Additionally, no system was in place to monitor immunization coverage in preschool-aged children, so obtaining an accurate picture of population susceptibility was not possible. Inevitably, this situation led to an accumulation of susceptible children and a consequent resurgence of measles by the end of the decade.

Which country was the first to be vaccinated?

References –

1. ^ Jump up to: a b “World Health Organization timeline – COVID-19”, World Health Organization (WHO).27 April 2020. Archived from the original on 29 April 2020, Retrieved 2 May 2020,
2. ^ Jump up to: a b c d e f g h i j k l Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, Mayhew S (May 2020). “The COVID-19 vaccine development landscape”, Nature Reviews. Drug Discovery,19 (5): 305–306. doi : 10.1038/d41573-020-00073-5, PMID 32273591,
3. ^ Jump up to: a b c d e f Gates B (February 2020). “Responding to Covid-19: A once-in-a-century pandemic?”, The New England Journal of Medicine,382 (18): 1677–79. doi : 10.1056/nejmp2003762, PMID 32109012,
4. ^ Jump up to: a b Fauci AS, Lane HC, Redfield RR (March 2020). “Covid-19: Navigating the uncharted”, The New England Journal of Medicine,382 (13): 1268–69. doi : 10.1056/nejme2002387, PMC 7121221, PMID 32109011,
5. ^ Jump up to: a b c d e f g h Le TT, Cramer JP, Chen R, Mayhew S (October 2020). “Evolution of the COVID-19 vaccine development landscape”, Nature Reviews. Drug Discovery,19 (10): 667–668. doi : 10.1038/d41573-020-00151-8, PMID 32887942, S2CID 221503034,
6. ^ Jump up to: a b c Weintraub R, Yadav P, Berkley S (2 April 2020). “A COVID-19 vaccine will need equitable, global distribution”, Harvard Business Review, ISSN 0017-8012, Archived from the original on 9 June 2020, Retrieved 9 June 2020,
7. ^ Jump up to: a b c “COVID-19 pandemic reveals the risks of relying on private sector for life-saving vaccines, says expert”, CBC Radio,8 May 2020. Archived from the original on 13 May 2020, Retrieved 8 June 2020,
8. ^ Jump up to: a b c d Ahmed DD (4 June 2020). “Oxford, AstraZeneca COVID-19 deal reinforces ‘vaccine sovereignty’ “, Stat, Archived from the original on 12 June 2020, Retrieved 8 June 2020,
9. ^ Jump up to: a b Grenfell R, Drew T (14 February 2020). “Here’s why the WHO says a coronavirus vaccine is 18 months away”, Business Insider, Archived from the original on 5 December 2020, Retrieved 11 November 2020,
10. ^ Offit, Paul. “TWiV 720: With vaccines, Offit is on it”, This Week in Virology Podcast, Vincent Racaniello Youtube Channel. Archived from the original on 25 May 2021, Retrieved 14 July 2021,
11. ^ Jump up to: a b c d e f “Update on WHO Solidarity Trial – Accelerating a safe and effective COVID-19 vaccine”, World Health Organization (WHO).27 April 2020. Archived from the original on 30 April 2020, Retrieved 2 May 2020, It is vital that we evaluate as many vaccines as possible as we cannot predict how many will turn out to be viable. To increase the chances of success (given the high level of attrition during vaccine development), we must test all candidate vaccines until they fail. WHO is working to ensure that all of them have the chance of being tested at the initial stage of development. The results for the efficacy of each vaccine are expected within three to six months and this evidence, combined with data on safety, will inform decisions about whether it can be used on a wider scale.
12. ^ Jump up to: a b c Yamey G, Schäferhoff M, Hatchett R, Pate M, Zhao F, McDade KK (May 2020). “Ensuring global access to COVID‑19 vaccines”, Lancet,395 (10234): 1405–06. doi : 10.1016/S0140-6736(20)30763-7, PMC 7271264, PMID 32243778, CEPI estimates that developing up to three vaccines in the next 12–18 months will require an investment of at least US$2 billion. This estimate includes Phase 1 clinical trials of eight vaccine candidates, progression of up to six candidates through Phase 2 and 3 trials, completion of regulatory and quality requirements for at least three vaccines, and enhancing global manufacturing capacity for three vaccines.
13. ^ Jump up to: a b “WHO ‘backed China’s emergency use’ of experimental Covid-19 vaccines”, South China Morning Post,25 September 2020. Archived from the original on 26 September 2020, Retrieved 26 September 2020,
14. ^ Jump up to: a b Kramer AE (19 September 2020). “Russia Is Slow to Administer Virus Vaccine Despite Kremlin’s Approval”, The New York Times, ISSN 0362-4331, Archived from the original on 27 September 2020, Retrieved 28 September 2020,
15. ^ Jump up to: a b “Pfizer and BioNTech to Submit Emergency Use Authorization Request Today to the U.S. FDA for COVID-19 Vaccine”, Pfizer (Press release).20 November 2020. Archived from the original on 29 January 2021, Retrieved 20 November 2020,
16. ^ Jump up to: a b Park A (20 November 2020). “Exclusive: Pfizer CEO Discusses Submitting the First COVID-19 Vaccine Clearance Request to the FDA”, Time, Archived from the original on 29 January 2021, Retrieved 20 November 2020,
17. ^ Jump up to: a b “Information for Healthcare Professionals on Pfizer/BioNTech COVID-19 vaccine”, Medicines & Healthcare products Regulatory Agency (MHRA),8 December 2020. Archived from the original on 15 March 2021, Retrieved 13 December 2020,
18. ^ Jump up to: a b “Conditions of Authorisation for Pfizer/BioNTech COVID-19 vaccine”, Medicines and Healthcare products Regulatory Agency (MHRA),3 December 2020. Archived from the original on 26 February 2021, Retrieved 19 December 2020,
19. ^ Jump up to: a b “UK medicines regulator gives approval for first UK COVID-19 vaccine”, Medicines and Healthcare Products Regulatory Agency, Government of the UK.2 December 2020. Archived from the original on 17 March 2021, Retrieved 2 December 2020,
20. ^ Jump up to: a b Mueller, Benjamin (2 December 2020). “U.K. Approves Pfizer Coronavirus Vaccine, a First in the West”, The New York Times, Archived from the original on 28 January 2021, Retrieved 2 December 2020,
21. ^ Jump up to: a b Roberts, Michelle (2 December 2020). “Covid Pfizer vaccine approved for use next week in UK”, BBC News Online, Archived from the original on 2 December 2020, Retrieved 2 December 2020,
22. ^ Jump up to: a b c “Questions and Answers: COVID-19 vaccination in the EU”, European Commission,21 December 2020. Archived from the original on 29 January 2021, Retrieved 21 December 2020,
23. ^ Jump up to: a b “Bahrain second in the world to approve the Pfizer/BioNTech Covid-19 vaccine”, Bahrain News Agency.4 December 2020. Archived from the original on 17 December 2020, Retrieved 9 December 2020,
24. ^ Jump up to: a b “UAE: Ministry of Health announces 86 per cent vaccine efficacy”, Gulf News, Archived from the original on 24 December 2020, Retrieved 9 December 2020,
25. ^ Jump up to: a b Thomas K, LaFraniere S, Weiland N, Goodnough A, Haberman M (12 December 2020). “F.D.A. Clears Pfizer Vaccine, and Millions of Doses Will Be Shipped Right Away”, The New York Times, Archived from the original on 12 December 2020, Retrieved 12 December 2020,
26. ^ Jump up to: a b c “FDA Takes Additional Action in Fight Against COVID-19 By Issuing Emergency Use Authorization for Second COVID-19 Vaccine”,U.S. Food and Drug Administration (FDA) (Press release). Archived from the original on 17 March 2021, Retrieved 18 December 2020,
27. ^ Jump up to: a b c Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (January 2021). “The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Moderna COVID-19 Vaccine – United States, December 2020” (PDF), MMWR. Morbidity and Mortality Weekly Report,69 (5152): 1653–56. doi : 10.15585/mmwr.mm695152e1, PMC 9191904, PMID 33382675, S2CID 229945697, Archived (PDF) from the original on 9 February 2021, Retrieved 18 January 2021,
28. ^ Jump up to: a b c Lovelace Jr B (19 December 2020). “FDA approves second Covid vaccine for emergency use as it clears Moderna’s for U.S. distribution”, CNBC. Archived from the original on 26 January 2021, Retrieved 19 December 2020,
29. ^ Corum J, Zimmer C. “How the Oxford-AstraZeneca Vaccine Works”, The New York Times, Archived from the original on 5 January 2022, Retrieved 2 May 2021,
30. ^ Tétrault-Farber M, Vasilyeva G (31 March 2021). “Russia registers world’s first COVID-19 vaccine for animals”, Reuters, Archived from the original on 17 December 2021, Retrieved 4 April 2021,
31. ^ ” COVID-19 “, TASS (in Russian). Moscow.31 March 2021. Archived from the original on 19 May 2021, Retrieved 19 May 2021,
32. ^ MORITSUGU, KEN (26 October 2022). “Afraid of needles? China using inhalable COVID-19 vaccine”, AP NEWS, Retrieved 2 November 2022,
33. ^ Jump up to: a b Hotez PJ, Bottazzi ME (January 2022). “Whole Inactivated Virus and Protein-Based COVID-19 Vaccines”, Annual Review of Medicine,73 (1): 55–64. doi : 10.1146/annurev-med-042420-113212, PMID 34637324, S2CID 238747462,
34. ^ Ye Y, Zhang Q, Wei X, Cao Z, Yuan HY, Zeng DD (February 2022). “Equitable access to COVID-19 vaccines makes a life-saving difference to all countries”, Nature Human Behaviour,6 (2): 207–216. doi : 10.1038/s41562-022-01289-8, PMC 8873023, PMID 35102361,
35. ^ Jump up to: a b c Gouglas D, Thanh Le T, Henderson K, Kaloudis A, Danielsen T, Hammersland NC, Robinson JM, Heaton PM, Røttingen JA (December 2018). “Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study”, Lancet Global Health,6 (12): e1386–96. doi : 10.1016/S2214-109X(18)30346-2, PMC 7164811, PMID 30342925,
36. ^ DiMasi JA, Grabowski HG, Hansen RW (May 2016). “Innovation in the pharmaceutical industry: New estimates of R&D costs”. Journal of Health Economics,47 : 20–33. doi : 10.1016/j.jhealeco.2016.01.012, hdl : 10161/12742, PMID 26928437,
37. ^ “G20 launches initiative for health tools needed to combat the coronavirus”,25 April 2020.
38. ^ “Access to COVID-19 Tools (ACT) Accelerator” (PDF), World Health Organization (WHO).24 April 2020.
39. ^ Moon, Suerie; Armstrong, Jana; Hutler, Brian; Upshur, Ross; Katz, Rachel; Atuire, Caesar; Bhan, Anant; Emanuel, Ezekiel; Faden, Ruth; Ghimire, Prakash; Greco, Dirceu (29 January 2022). “Governing the Access to COVID-19 Tools Accelerator: towards greater participation, transparency, and accountability”, The Lancet,399 (10323): 487–494. doi : 10.1016/S0140-6736(21)02344-8, ISSN 0140-6736, PMC 8797025, PMID 34902308,
40. ^ Abedi M (23 March 2020). “Canada to spend $192M on developing COVID-19 vaccine”, Global News, Archived from the original on 9 April 2020, Retrieved 24 March 2020,
41. ^ “Government of Canada funds 49 additional COVID-19 research projects – Details of the funded projects”, Government of Canada.23 March 2020. Archived from the original on 22 March 2020, Retrieved 23 March 2020,
42. ^ “Government of Canada’s research response to COVID-19”, Government of Canada.23 April 2020. Archived from the original on 13 May 2020, Retrieved 4 May 2020,
43. ^ Aiello R (4 May 2020). ” ‘A global challenge’: PM Trudeau commits $850 million to global fight against COVID-19″, CTV News, Archived from the original on 10 May 2020, Retrieved 4 May 2020,
44. ^ Jump up to: a b c d Steenhuysen J, Eisler P, Martell A, Nebehay S (27 April 2020). “Special Report: Countries, companies risk billions in race for coronavirus vaccine”, Reuters. Archived from the original on 15 May 2020, Retrieved 2 May 2020,
45. ^ Jump up to: a b c d Sanger DE, Kirkpatrick DD, Zimmer C, Thomas K, Wee S (2 May 2020). “With Pressure Growing, Global Race for a Vaccine Intensifies”, The New York Times, ISSN 0362-4331, Archived from the original on 11 May 2020, Retrieved 2 May 2020,
46. ^ Takada N, Satake M (2 May 2020). “US and China unleash wallets in race for coronavirus vaccine”, Nikkei Asian Review, Archived from the original on 10 May 2020, Retrieved 3 May 2020,
47. ^ Talmazan, Yuliya; Simmons, Keir; Saravia, Laura (18 May 2020). “China’s Xi announces $2B for coronavirus response as WHO faces calls for investigation”, NBC News, Archived from the original on 18 May 2020, Retrieved 18 May 2020,
48. ^ Ore D (23 July 2020). “Mexico says China plans $1 billion loan to ease Latam access to virus vaccine”, Reuters. Archived from the original on 25 September 2020, Retrieved 16 August 2020,
49. ^ “China promises Mekong neighbours access to Chinese Covid-19 vaccine”, South China Morning Post,24 August 2020. Archived from the original on 25 September 2020, Retrieved 24 August 2020,
50. ^ Morriss E (22 April 2020). “Government launches coronavirus vaccine taskforce as human clinical trials start”, Pharmafield. Archived from the original on 26 June 2020, Retrieved 3 May 2020,
51. ^ Gartner A, Roberts L (3 May 2020). “How close are we to a coronavirus vaccine? Latest news on UK trials”, The Telegraph, ISSN 0307-1235, Archived from the original on 4 May 2020, Retrieved 3 May 2020,
52. ^ “Landmark partnership announced for development of COVID-19 vaccine”, University of Oxford.30 April 2020. Archived from the original on 13 May 2020, Retrieved 3 May 2020,
53. ^ Jump up to: a b Kuznia R, Polglase K, Mezzofiore G (1 May 2020). “In quest for vaccine, US makes ‘big bet’ on company with unproven technology”, CNN. Archived from the original on 13 May 2020, Retrieved 2 May 2020,
54. ^ Lee CE, Welker K, Perlmutter-Gumbiner E (1 May 2020). “Health officials eyeing at least one of 14 potential coronavirus vaccines to fast-track”, NBC News, Archived from the original on 11 May 2020, Retrieved 2 May 2020,
55. ^ Cohen J (15 May 2020). “U.S. ‘Warp Speed’ vaccine effort comes out of the shadows”, Science,368 (6492): 692–93. Bibcode : 2020Sci.368.692C, doi : 10.1126/science.368.6492.692, ISSN 0036-8075, PMID 32409451,
56. ^ Sink J, Fabian J, Griffin R (15 May 2020). “Trump introduces ‘Warp Speed’ leaders to hasten COVID-19 vaccine”, Bloomberg, Archived from the original on 21 May 2020, Retrieved 15 May 2020,
57. ^ Griffith R, Jacobs J (3 June 2020). “White House Works With Seven Drugmakers in ‘Warp Speed’ Push”, Bloomberg, Archived from the original on 3 June 2020, Retrieved 4 June 2020,
58. ^ “Fact-checking the battle for credit over Pfizer’s vaccine announcement”, CNN. Archived from the original on 16 November 2020, Retrieved 13 November 2020, Pfizer is one of various vaccine manufacturers participating in Operation Warp Speed as a supplier of a potential COVID-19 vaccine,” Castillo said in an email. “While Pfizer did reach an advanced purchase agreement with the U.S. government, the company did not accept (Biomedical Advanced Research and Development Authority) funding for the research and development process. All the investment for R&D was made by Pfizer at risk. Dr. Jansen was emphasizing that last point.
59. ^ McGrail S (15 April 2020). “Sanofi, GSK partner to develop adjuvanted COVID-19 vaccine”, PharmaNewsIntelligence. Archived from the original on 9 May 2020, Retrieved 4 May 2020,
60. ^ Blankenship K (4 June 2020). “AstraZeneca unveils massive $750M deal in effort to produce billions of COVID-19 shots”, FiercePharma. Archived from the original on 10 June 2020, Retrieved 8 June 2020,
61. ^ Jump up to: a b Cohen J (4 June 2020). “Top U.S. scientists left out of White House selection of COVID-19 vaccine short list”, Science, doi : 10.1126/science.abd1719, ISSN 0036-8075,
62. ^ Schmidt C (1 June 2020). “Genetic Engineering Could Make a COVID-19 Vaccine in Months Rather Than Years”, Scientific American, Archived from the original on 11 October 2020, Retrieved 26 August 2020,
63. ^ Jump up to: a b Gates B (30 April 2020). “The vaccine race explained: What you need to know about the COVID-19 vaccine”, The Gates Notes. Archived from the original on 14 May 2020, Retrieved 2 May 2020,
64. ^ Fox C, Kelion L (16 July 2020). “Russian spies ‘target coronavirus vaccine’ “, BBC News, Archived from the original on 11 October 2020, Retrieved 1 August 2020,
65. ^ Jump up to: a b Coronavirus: North Korea and Russia hackers ‘targeting vaccine’ Archived 17 December 2021 at the Wayback Machine, (13 November 2020).
66. ^ Jump up to: a b North Korea accused of hacking Pfizer for Covid-19 vaccine data Archived 24 April 2022 at the Wayback Machine, BBC News (16 February 2021).
67. ^ “Public statement for collaboration on COVID-19 vaccine development”, World Health Organization (WHO).13 April 2020. Archived from the original on 20 April 2020, Retrieved 20 April 2020,
68. ^ Jump up to: a b “Clinical Development Success Rates 2006–2015” (PDF), BIO Industry Analysis. June 2016. Archived (PDF) from the original on 12 September 2019, Retrieved 23 March 2020,
69. ^ Pandamooz, Sareh; Jurek, Benjamin; Meinung, Carl-Philipp; Baharvand, Zahra; Sahebi Shahem-abadi, Alireza; Haerteis, Silke; Miyan, Jaleel A.; Downing, James; Dianatpour, Mehdi; Borhani-Haghighi, Afshin; Salehi, Mohammad Saied (6 January 2022). “Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments”, Annual Review of Pharmacology and Toxicology,62 (1): 25–53. doi : 10.1146/annurev-pharmtox-121120-012309, ISSN 0362-1642, PMID 33606962, S2CID 231970935, Archived from the original on 17 June 2022, Retrieved 18 April 2022,
70. ^ Jump up to: a b c d e Diamond MS, Pierson TC (May 2020). “The Challenges of Vaccine Development against a New Virus during a Pandemic”, Cell Host & Microbe,27 (5): 699–703. doi : 10.1016/j.chom.2020.04.021, PMC 7219397, PMID 32407708,
71. ^ Thorp HH (March 2020). “Underpromise, overdeliver”, Science,367 (6485): 1405. Bibcode : 2020Sci.367.1405T, doi : 10.1126/science.abb8492, PMID 32205459,
72. ^ Blackwell T (20 April 2020). “COVID-19 vaccine researchers say pandemic lockdown placing many serious obstacles to their work”, National Post, Archived from the original on 23 April 2020, Retrieved 3 May 2020,
73. ^ Chen J (4 May 2020). “Covid-19 has shuttered labs. It could put a generation of researchers at risk”, Stat, Archived from the original on 6 May 2020, Retrieved 4 May 2020,
74. ^ Jump up to: a b c Iwasaki A, Yang Y (June 2020). “The potential danger of suboptimal antibody responses in COVID-19”, Nature Reviews. Immunology,20 (6): 339–341. doi : 10.1038/s41577-020-0321-6, PMC 7187142, PMID 32317716,
75. ^ Lambert PH, Ambrosino DM, Andersen SR, Baric RS, Black SB, Chen RT, et al. (June 2020). “Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines”, Vaccine,38 (31): 4783–4791. doi : 10.1016/j.vaccine.2020.05.064, PMC 7247514, PMID 32507409,
76. ^ Jump up to: a b Haynes, Barton F.; Corey, Lawrence; Fernandes, Prabhavathi; Gilbert, Peter B.; Hotez, Peter J.; Rao, Srinivas; Santos, Michael R.; Schuitemaker, Hanneke; Watson, Michael; Arvin, Ann (4 November 2020). “Prospects for a safe COVID-19 vaccine”, Science Translational Medicine,12 (568): eabe0948. doi : 10.1126/scitranslmed.abe0948, ISSN 1946-6242, PMID 33077678, S2CID 224809822, Archived from the original on 17 February 2022, Retrieved 15 April 2022,
77. ^ Hackethal V (16 March 2021). “Why ADE Hasn’t Been a Problem With COVID Vaccines”, www.medpagetoday.com, Archived from the original on 25 June 2021, Retrieved 1 July 2021,
78. ^ “Draft landscape of COVID 19 candidate vaccines”, World Health Organization (WHO).10 December 2020. Archived from the original on 30 April 2020, Retrieved 11 December 2020,
79. ^ Jump up to: a b c d “An international randomised trial of candidate vaccines against COVID-19: Outline of Solidarity vaccine trial” (PDF), World Health Organization (WHO).9 April 2020. Archived (PDF) from the original on 12 May 2020, Retrieved 9 May 2020,
80. ^ Jump up to: a b “Vaccine Safety – Vaccines”, vaccines.gov, US Department of Health and Human Services. Archived from the original on 22 April 2020, Retrieved 13 April 2020,
81. ^ Jump up to: a b c “The drug development process”,U.S. Food and Drug Administration (FDA).4 January 2018. Archived from the original on 22 February 2020, Retrieved 12 April 2020,
82. ^ Jump up to: a b c d e Cohen J (June 2020). “Pandemic vaccines are about to face the real test”, Science,368 (6497): 1295–1296. Bibcode : 2020Sci.368.1295C, doi : 10.1126/science.368.6497.1295, PMID 32554572,
83. ^ “How flu vaccine effectiveness and efficacy are measured”, Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases, US Department of Health and Human Services.29 January 2016. Archived from the original on 7 May 2020, Retrieved 6 May 2020,
84. ^ “Principles of epidemiology, Section 8: Concepts of disease occurrence”, Centers for Disease Control and Prevention, Center for Surveillance, Epidemiology, and Laboratory Services, US Department of Health and Human Services.18 May 2012. Archived from the original on 6 April 2020, Retrieved 6 May 2020,
85. ^ Jump up to: a b AstraZeneca (12 April 2021). “A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Study in Adults, to Determine the Safety, Efficacy, and Immunogenicity of AZD1222, a Non-replicating ChAdOx1 Vector Vaccine, for the Prevention of COVID-19”, Iqvia Pty Ltd. Archived from the original on 23 August 2020, Retrieved 11 June 2021,
86. ^ Covid news live: England drops all ‘plan B’ restrictions; Moderna begins trial of Omicron-specific booster shot Archived 29 January 2022 at the Wayback Machine The Guardian
87. ^ Dubé E, Laberge C, Guay M, Bramadat P, Roy R, Bettinger J (August 2013). “Vaccine hesitancy: an overview”, Human Vaccines & Immunotherapeutics,9 (8): 1763–73. doi : 10.4161/hv.24657, PMC 3906279, PMID 23584253,
88. ^ Howard J, Stracqualursi V (18 June 2020). “Fauci warns of ‘anti-science bias’ being a problem in US”, CNN. Archived from the original on 21 June 2020, Retrieved 21 June 2020,
89. ^ Winter SS, Page-Reeves JM, Page KA, Haozous E, Solares A, Nicole Cordova C, Larson RS (May 2018). “Inclusion of special populations in clinical research: important considerations and guidelines”, Journal of Clinical and Translational Research (Review).4 (1): 56–69. PMC 6410628, PMID 30873495,
90. ^ Jump up to: a b Pallmann P, Bedding AW, Choodari-Oskooei B, Dimairo M, Flight L, Hampson LV, et al. (February 2018). “Adaptive designs in clinical trials: why use them, and how to run and report them”, BMC Medicine,16 (1): 29. doi : 10.1186/s12916-018-1017-7, PMC 5830330, PMID 29490655,
91. ^ “Adaptive designs for clinical trials of drugs and biologics: Guidance for industry” (PDF),U.S. Food and Drug Administration (FDA).1 November 2019. Archived from the original on 13 December 2019, Retrieved 3 April 2020,
92. ^ Lambkin-Williams R, Noulin N, Mann A, Catchpole A, Gilbert AS (June 2018). “The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics”, Respiratory Research,19 (1): 123. doi : 10.1186/s12931-018-0784-1, PMC 6013893, PMID 29929556,
93. ^ Jump up to: a b Eyal N, Lipsitch M, Smith PG (May 2020). “Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure”, The Journal of Infectious Diseases,221 (11): 1752–1756. doi : 10.1093/infdis/jiaa152, PMC 7184325, PMID 32232474,
94. ^ Jump up to: a b c Callaway E (April 2020). “Should scientists infect healthy people with the coronavirus to test vaccines?”, Nature,580 (7801): 17. Bibcode : 2020Natur.580.17C, doi : 10.1038/d41586-020-00927-3, PMID 32218549,
95. ^ Jump up to: a b Cohen J (31 March 2020). “Speed coronavirus vaccine testing by deliberately infecting volunteers? Not so fast, some scientists warn”, Science, doi : 10.1126/science.abc0006,
96. ^ “Key criteria for the ethical acceptability of COVID-19 human challenge studies” (PDF), World Health Organization (WHO).6 May 2020. Archived (PDF) from the original on 8 May 2020, Retrieved 12 May 2020,
97. ^ Jump up to: a b Callaway E (October 2020). “Dozens to be deliberately infected with coronavirus in UK ‘human challenge’ trials”, Nature,586 (7831): 651–652. Bibcode : 2020Natur.586.651C, doi : 10.1038/d41586-020-02821-4, PMID 33082550, S2CID 224823112,
98. ^ Jump up to: a b “WHO publishes Emergency Use Listing procedure and roadmap to make new medical products more readily available during health emergencies” (Press release). World Health Organization (WHO).9 January 2020. Archived from the original on 29 September 2020, Retrieved 23 August 2020,
99. ^ “Vaccines: The Emergency Authorisation Procedure”, European Medicines Agency.2020. Archived from the original on 24 September 2020, Retrieved 21 August 2020,
100. ^ Byrne, Jane (19 October 2020). “Moderna COVID-19 vaccine under rolling review process in Canada, EU”, BioPharma-Reporter.com, William Reed Business Media Ltd. Archived from the original on 25 February 2021, Retrieved 25 November 2020,
101. ^ Dangerfield, Katie (20 November 2020). “Pfizer files for emergency use of coronavirus vaccine in U.S. – what about in Canada?”, Global News, Archived from the original on 25 January 2021, Retrieved 25 November 2020,
102. ^ “Coronavirus: UAE authorises emergency use of vaccine for frontline workers”, The National,14 September 2020. Archived from the original on 2 January 2020, Retrieved 18 November 2020,
103. ^ Barrington L (3 November 2020). “Bahrain latest country to vaccinate frontline workers with COVID-19 shot”, Reuters. Archived from the original on 30 December 2021, Retrieved 18 November 2020,
104. ^ Jump up to: a b “Emergency Use Authorization for Vaccines Explained”,U.S. Food and Drug Administration (FDA),20 November 2020. Archived from the original on 20 November 2020, Retrieved 20 November 2020, This article incorporates text from this source, which is in the public domain,
105. ^ Malik AA, McFadden SM, Elharake J, Omer SB (September 2020). “Determinants of COVID-19 vaccine acceptance in the US”, eClinicalMedicine,26 : 100495. doi : 10.1016/j.eclinm.2020.100495, PMC 7423333, PMID 32838242,
106. ^ “FDA may be risk-averse to grant emergency use for a Covid-19 vaccine; political pressure and hazy EUA standards are factors”, ClinicalTrials Arena, Verdict Media, Ltd.2 July 2020. Archived from the original on 22 July 2020, Retrieved 22 August 2020,
107. ^ Hoffman J (18 July 2020). “Mistrust of a coronavirus vaccine could imperil widespread immunity”, The New York Times, Archived from the original on 27 September 2020, Retrieved 23 August 2020,
108. ^ “Biopharma Leaders Unite to Stand with Science” (Press release).8 September 2020. Archived from the original on 1 January 2021, Retrieved 31 December 2020 – via Business Wire.
109. ^ “Covid-19 vaccine: Margaret Keenan ‘so privileged’ to get first jab”, BBC News Online,8 December 2020. Archived from the original on 8 December 2020, Retrieved 8 December 2020,
110. ^ Mueller, Benjamin (8 December 2020). “As U.K. Begins Vaccinations, a Glimpse of Life After Covid”, The New York Times, Archived from the original on 14 December 2020, Retrieved 20 December 2020,
111. ^ “Covid: Russia begins vaccinations in Moscow”, BBC News Online,5 December 2020. Archived from the original on 1 June 2022, Retrieved 18 January 2021,
112. ^ Oliver SE, Gargano JW, Marin M, Wallace M, Curran KG, Chamberland M, et al. (December 2020). “The Advisory Committee on Immunization Practices’ Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine – United States, December 2020” (PDF), MMWR. Morbidity and Mortality Weekly Report,69 (50): 1922–24. doi : 10.15585/mmwr.mm6950e2, PMC 7745957, PMID 33332292, Archived (PDF) from the original on 19 December 2020, Retrieved 18 January 2021,
113. ^ “Swissmedic grants authorisation for the first COVID-19 vaccine in Switzerland” (Press release). Swiss Agency for Therapeutic Products (Swissmedic),19 December 2020. Archived from the original on 10 January 2021, Retrieved 19 December 2020,
114. ^ “COVID-19: Switzerland can start vaccinating vulnerable groups already in December” (Press release). Swiss Federal Office of Public Health.19 December 2020. Archived from the original on 9 January 2021, Retrieved 19 December 2020,
115. ^ Pralong, Julien (23 December 2020). “La piqûre de l’espoir pratiquée à Lucerne”, Heidi.news, Archived from the original on 10 January 2021, Retrieved 23 December 2020,
116. ^ Campbell, Denis (16 December 2020). “138,000 people in UK receive Covid vaccine in first week”, The Guardian, Archived from the original on 25 March 2022, Retrieved 18 January 2021,
117. ^ Herper M (15 December 2020). “Inside the frantic and secretive sprint to name the Covid-19 vaccines”, Stat, Archived from the original on 17 December 2020, Retrieved 19 December 2020,
118. ^ Bird S (14 November 2020). “Trademark filings offer tantalising glimpse of coronavirus vaccine’s name”, The Daily Telegraph, Archived from the original on 12 January 2022, Retrieved 19 December 2020,
119. ^ “Moderna Applies for Emergency F.D.A. Approval for Its Coronavirus Vaccine”, The New York Times,30 November 2020. Archived from the original on 30 November 2020, Retrieved 30 November 2020,
120. ^ “Moderna Announces Primary Efficacy Analysis in Phase 3 COVE Study for Its COVID-19 Vaccine Candidate and Filing Today with U.S. FDA for Emergency Use Authorization”, Moderna, Inc. (Press release).30 November 2020. Archived from the original on 30 November 2020, Retrieved 30 November 2020,
121. ^ “Oxford University/AstraZeneca vaccine authorised by UK medicines regulator”, Gov.uk, Department of Health and Social Care.30 December 2020. Archived from the original on 16 March 2021, Retrieved 30 December 2020,
122. ^ “Information for Healthcare Professionals on COVID-19 Vaccine AstraZeneca”, Medicines and Healthcare products Regulatory Agency (MHRA),30 December 2020. Archived from the original on 9 March 2021, Retrieved 4 January 2021,
123. ^ “Conditions of Authorisation for COVID-19 Vaccine AstraZeneca”, Medicines and Healthcare products Regulatory Agency (MHRA),30 December 2020. Archived from the original on 18 February 2021, Retrieved 4 January 2021,
124. ^ “TGA grants provisional determination for COVID-19 vaccine”, Therapeutic Goods Administration (TGA),9 October 2020. Archived from the original on 29 October 2020, Retrieved 25 October 2020,
125. ^ “TGA grants second provisional determination for a COVID-19 vaccine”, Therapeutic Goods Administration (TGA),14 October 2020. Archived from the original on 28 October 2020, Retrieved 25 October 2020,
126. ^ “TGA grants third provisional determination for a COVID-19 vaccine”, Therapeutic Goods Administration (TGA),16 November 2020. Archived from the original on 16 January 2021, Retrieved 19 December 2020,
127. ^ “Comirnaty”, Therapeutic Goods Administration,25 January 2021. Archived from the original on 1 February 2021, Retrieved 25 January 2021,
128. ^ “TGA provisionally approves Pfizer COVID-19 vaccine”, Therapeutic Goods Administration (TGA) (Press release).25 January 2021. Archived from the original on 26 January 2021, Retrieved 25 January 2021,
129. ^ “Comirnaty (BNT162b2 ) COVID‑19 Vaccine Product Information” (PDF), Therapeutic Goods Administration (TGA), Archived from the original on 2 February 2021, Retrieved 25 January 2021,
130. ^ Australian Public Assessment Report for BNT162b2 (mRNA) (PDF) (Report). Therapeutic Goods Administration (TGA). Archived (PDF) from the original on 26 January 2021, Retrieved 25 January 2021,
131. ^ “Elasomeran”, Therapeutic Goods Administration,24 June 2021. Archived from the original on 27 June 2021, Retrieved 18 August 2021,
132. ^ “EMA starts first rolling review of a COVID-19 vaccine in the EU” (Press release). European Medicines Agency (EMA).1 October 2020. Archived from the original on 1 October 2020, Retrieved 1 October 2020,
133. ^ “COVID-19 vaccines: key facts”, European Medicines Agency (EMA).14 September 2020. Archived from the original on 7 October 2020, Retrieved 1 October 2020,
134. ^ “EMA starts second rolling review of a COVID-19 vaccine” (Press release). European Medicines Agency (EMA).5 October 2020. Archived from the original on 6 October 2020, Retrieved 6 October 2020,
135. ^ “Update on rolling review of AstraZeneca’s COVID-19 vaccine” (Press release). European Medicines Agency (EMA).30 December 2020. Archived from the original on 30 December 2020, Retrieved 30 December 2020,
136. ^ Jump up to: a b c “EMA publishes safety monitoring plan and guidance on risk management planning for COVID-19 vaccines” (Press release). European Medicines Agency (EMA).13 November 2020. Archived from the original on 13 November 2020, Retrieved 13 November 2020, Text was copied from this source which is European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
137. ^ “EMA considerations on COVID-19 vaccine approval”, European Medicines Agency (EMA).19 November 2020. Archived from the original on 19 November 2020, Retrieved 19 November 2020,
138. ^ “EMA starts rolling review of mRNA COVID-19 vaccine by Moderna Biotech Spain, S.L.” (Press release). European Medicines Agency (EMA).16 November 2020. Archived from the original on 16 November 2020, Retrieved 16 November 2020,
139. ^ Jump up to: a b “EMA receives application for conditional marketing authorisation of Moderna COVID-19 vaccine” (Press release). European Medicines Agency (EMA).1 December 2020. Archived from the original on 1 December 2020, Retrieved 1 December 2020,
140. ^ Jump up to: a b “EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2” (Press release). European Medicines Agency (EMA).1 December 2020. Archived from the original on 1 December 2020, Retrieved 1 December 2020,
141. ^ “Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application” (Press release). European Medicines Agency (EMA).15 December 2020. Archived from the original on 15 December 2020, Retrieved 15 December 2020,
142. ^ “Update on assessment of marketing authorisation application for Moderna’s mRNA-1273 COVID-19 vaccine” (Press release). European Medicines Agency (EMA).17 December 2020. Archived from the original on 17 December 2020, Retrieved 17 December 2020,
143. ^ “EMA starts rolling review of Janssen’s COVID-19 vaccine Ad26.COV2.S” (Press release). European Medicines Agency (EMA).1 December 2020. Archived from the original on 8 January 2021, Retrieved 1 December 2020,
144. ^ Jump up to: a b “EMA recommends first COVID-19 vaccine for authorisation in the EU” (Press release). European Medicines Agency (EMA).21 December 2020. Archived from the original on 30 January 2021, Retrieved 21 December 2020,
145. ^ “Comirnaty EPAR”, European Medicines Agency (EMA).21 December 2020. Archived from the original on 24 January 2022, Retrieved 23 December 2020,
146. ^ “Statement by President von der Leyen on the marketing authorisation of the BioNTech-Pfizer vaccine against COVID-19”, European Commission, Archived from the original on 11 January 2021, Retrieved 21 December 2020,
147. ^ “Comirnaty”, Union Register of medicinal products, Archived from the original on 24 January 2021, Retrieved 29 January 2021,
148. ^ Jump up to: a b Cavaleri M, Enzmann H, Straus S, Cooke E (January 2021). “The European Medicines Agency’s EU conditional marketing authorisations for COVID-19 vaccines”, Lancet,397 (10272): 355–357. doi : 10.1016/s0140-6736(21)00085-4, ISSN 0140-6736, PMC 7833511, PMID 33453149,
149. ^ “COVID-19 Vaccine Moderna EPAR”, European Medicines Agency (EMA).4 January 2021. Archived from the original on 12 March 2021, Retrieved 20 January 2021,
150. ^ “EMA recommends COVID-19 Vaccine Moderna for authorisation in the EU” (Press release). European Medicines Agency.6 January 2021. Archived from the original on 17 March 2021, Retrieved 6 January 2021,
151. ^ “European Commission authorises second safe and effective vaccine against COVID-19”, European Commission (Press release). Archived from the original on 20 January 2021, Retrieved 6 January 2021,
152. ^ “COVID-19 Vaccine Moderna”, Union Register of medicinal products, Archived from the original on 24 January 2021, Retrieved 14 January 2021,
153. ^ “EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca”, European Medicines Agency (EMA).12 January 2021. Archived from the original on 30 March 2021, Retrieved 12 January 2021,
154. ^ “COVID-19 Vaccine AstraZeneca”, European Medicines Agency (EMA).28 January 2021. Archived from the original on 16 February 2021, Retrieved 29 January 2021,
155. ^ “EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU” (Press release). European Medicines Agency (EMA).29 January 2021. Archived from the original on 9 February 2021, Retrieved 29 January 2021,
156. ^ “European Commission authorises third safe and effective vaccine against COVID-19”, European Commission (Press release). Archived from the original on 10 February 2021, Retrieved 29 January 2021,
157. ^ “COVID-19 Vaccine AstraZeneca”, Union Register of medicinal products, Archived from the original on 26 March 2021, Retrieved 29 January 2021,
158. ^ “EMA starts rolling review of Novavax’s COVID-19 vaccine (NVX-CoV2373)”, European Medicines Agency (EMA).3 February 2021. Archived from the original on 2 July 2021, Retrieved 3 February 2021, Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
159. ^ “EMA starts rolling review of CureVac’s COVID-19 vaccine (CVnCoV)” (Press release). European Medicines Agency (EMA).11 February 2021. Archived from the original on 12 February 2021, Retrieved 12 February 2021,
160. ^ “EMA preparing guidance to tackle COVID-19 variants” (Press release). European Medicines Agency (EMA).10 February 2021. Archived from the original on 15 February 2021, Retrieved 10 February 2021,
161. ^ “EMA receives application for conditional marketing authorisation of COVID-19 Vaccine Janssen”, European Medicines Agency (EMA).16 February 2021. Archived from the original on 16 February 2021, Retrieved 16 February 2021,
162. ^ “COVID-19 Vaccine Janssen EPAR”, European Medicines Agency (EMA),5 March 2021. Archived from the original on 15 March 2021, Retrieved 11 July 2021,
163. ^ “EMA recommends COVID-19 Vaccine Janssen for authorisation in the EU”, European Medicines Agency (EMA) (Press release).11 March 2021. Archived from the original on 11 March 2021, Retrieved 11 July 2021,
164. ^ “European Commission authorises fourth safe and effective vaccine against COVID-19”, European Commission (Press release). Archived from the original on 25 August 2020, Retrieved 11 July 2021,
165. ^ Jump up to: a b “EMA starts rolling review of the Sputnik V COVID-19 vaccine” (Press release). European Medicines Agency (EMA).4 March 2021. Archived from the original on 4 March 2021, Retrieved 4 March 2021,
166. ^ “EMA starts evaluating use of COVID-19 vaccine Comirnaty in young people aged 12 to 15”, European Medicines Agency (EMA) (Press release).3 May 2021. Archived from the original on 7 May 2021, Retrieved 7 May 2021,
167. ^ Jump up to: a b “EMA starts rolling review of COVID-19 Vaccine (Vero Cell) Inactivated”, European Medicines Agency (EMA) (Press release).4 May 2021. Archived from the original on 4 May 2021, Retrieved 7 May 2021,

Who invented vaccinated?

1400s to 1700s – From at least the 15th century, people in different parts of the world have attempted to prevent illness by intentionally exposing healthy people to smallpox – a practice known as variolation (after a name for smallpox, ‘la variole’). Some sources suggest these practices were taking place as early as 200 BCE. From at least the 15th century, people in different parts of the world attempt to prevent illness by intentionally exposing healthy people to smallpox. © Credits In 1721, Lady Mary Wortley Montagu brought smallpox inoculation to Europe, by asking that her two daughters be inoculated against smallpox as she had observed practice in Turkey. Dr Edward Jenner created the world’s first successful vaccine. He found out that people infected with cowpox were immune to smallpox. © Credits In May 1796, English physician Edward Jenner expands on this discovery and inoculates 8-year-old James Phipps with matter collected from a cowpox sore on the hand of a milkmaid.

Despite suffering a local reaction and feeling unwell for several days, Phipps made a full recovery. Two months later, in July 1796, Jenner inoculates Phipps with matter from a human smallpox sore in order to test Phipps’ resistance. Phipps remains in perfect health, and becomes the first human to be vaccinated against smallpox.

The term ‘vaccine’ is later coined, taken from the Latin word for cow, vacca. Read more about the history of Smallpox vaccination, French Emperor Napoleon Bonaparte and American President Thomas Jefferson acknowledge Dr Edward Jenner’s work and endorse the smallpox vaccine. © Credits

Who approves Vaccines in us?

How New Vaccines Are Developed – The U.S. Food and Drug Administration’s (FDA’s) (CBER) is responsible for regulating vaccine use in the United States. The general stages of vaccine development are:

Research and Discovery Proof of Concept Testing the Vaccine The Manufacturing Process Approving the Vaccine Recommending the Vaccine for Use Monitoring Safety After Approval

Who is the biggest vaccine supplier?

Pfizer. After a record-breaking year, it’s no surprise Pfizer climbed to the top of the top of the vaccines industry.

Who is father of immunology?

Introduction – As a student of immunology, I learned that Louis Pasteur was really the father of immunology, despite Edward Jenner’s pioneering introduction of vaccination to prevent smallpox in 1798 (Smith, 2011 ). Although successful, Jenner’s experiments led to no understanding as to how immunity develops. By comparison, in addition to his many contributions to microbiology, Pasteur introduced the concept that vaccination could be applied to any microbial disease, and he reported methods as to how the virulence of microbes could attenuated so that live microbes could be used to make prophylactic vaccines that could be made in the laboratory and manufactured in unlimited quantities for use worldwide. As if that were not enough, Pasteur also introduced the concept of therapeutic vaccines with his studies of rabies. Thus, he showed that what we now call post-infection prophylaxis could be used to treat individuals who were exposed to a virulent organism, and if applied soon enough after infection, clinical disease and death could be averted. Thus, he offered the hope that infectious microbial diseases could be both prevented and treated via immunology. Of course, Pasteur was working at the dawn of microbiology, and using careful quantitative methods, he had already shown that microbes such as yeasts caused fermentation of sugar to produce alcohol, and as well, microbes are responsible for putrefaction, or the decay of tissues. Also, over 20 years, he extended his experiments to show that spoilage associated with the dairy, beer, wine, vinegar, and silk industries was explicable by contamination with bacteria. He is credited with the introduction of “pasteurization,” a process of heating to a sub-boiling point for a brief time, followed by rapid cooling, to kill most microbes. Toward the end of his career, Pasteur moved from microbiology to the study of vaccines, a natural extension, to try to prevent infectious diseases in domestic animals. This change in scientific emphasis necessitated him to gain expertise in handling both small and large animals. To help him in this new experimental direction, Pasteur employed a young physician, Emil Roux. As I too became interested in vaccines later in my career, I began to wonder about Pasteur’s pioneering vaccine work, especially the idea that it was important to use live attenuated microbes to generate immunity. Between the 1880s and the mid twentieth century, no one had reproduced Pasteur’s work, attenuating bacteria to make vaccines. One vaccine had been generated using Pasteur’s principles, the live attenuated Yellow Fever Virus vaccine, which was created in the 1930s (Theiler and Smith, 1936 ). However, reading about this work now, I realized that the attenuated Yellow Fever Virus vaccine was made possible by a single random mutation, so that luck had a great deal to do with this vaccine. At the time of Pasteur’s work, the term virus, derived from the Latin, meaning “poison,” was used generally to describe any agent that was found to cause an infectious disease. In the latter half of the nineteenth century techniques introduced by Pasteur, Robert Koch, and others to cultivate these “viruses,” ultimately led to the discovery and identification of a myriad of bacteria. At the time, due to Pasteur’s work, microbes could be discriminated by the use of very fine filters. Those microbes that could be removed by filtration were relatively large and could be cultivated outside the body and observed to form colonies observable by the naked eye. These microbes were subsequently classified as belonging to the Kingdom of Bacteria. Other poisons were smaller and passed through the filters into the filtrate. These became know as viruses, and a filterable agent was the working definition of a virus until the 1940s and 1950s, when the electron microscope allowed a magnification of 10 million times, powerful enough to enable their visualization. With this as a background, I wondered how Pasteur had attenuated the microbes that he used for his live vaccines, especially the attenuation of bacteria. From experiments beginning in the 1950s, it became known that viruses, such as poliovirus, could be attenuated by prolonged passage in tissue culture, but exactly how this worked in many instances remained unknown until recently. Now, we know that prolonged passaging of viruses in tissue culture cells allows for the accumulation of many spontaneous random mutations throughout the genome. However, exactly which of the mutations cause the loss of virulence of a particular organism usually remains obscure, even today. Therefore, how was Pasteur so brilliant that he could have accomplished this feat with bacteria more than 100 years ago? We still cannot attenuate bacteria easily. We now know that bacteria contain >4000 genes, while viruses contain ∼10–100 genes. Moreover, bacteria have their own viruses that can introduce virulence encoding genes. Consequently, unless one knows which of the >4000 genes are responsible for the virulence of a particular bacterium, it is impossible to attenuate its virulence simply by passaging it many times in vitro, Now, most of our vaccines against bacterial diseases are not live attenuated organisms. Instead, they consist of parts of the microbe, and are called subunit vaccines, and by definition, they are not living. And how could he have attenuated the rabies microbe, which is now known to be a virus and not a bacterium? And why did his therapeutic vaccine for rabies work so well? We would love to create such a vaccine for diseases such as the Acquired Immunodeficiency Syndrome, due to infection by the Human Immunodeficiency virus. Therefore, it is timely to re-examine Pasteur’s methods and findings.

How many vaccines available worldwide?

Immunization Protects Health, Communities, and Economies From Vaccine-Preventable Disease Threats –

There are more than 25 safe and effective vaccines to prevent diseases, protect health throughout the lifespan, and help to prevent and mitigate outbreaks. $52 saved per $1 spent is the return on investment from immunization programs in low- and middle-income countries. It costs $18 per child to fully immunize children in low-income countries, reduced from over $24 in 2013.

Learn about what CDC is doing to improve health equity by prioritizing access and delivery of lifesaving vaccines.

Who makes Soberana vaccine?

Soberana 02 or Soberana 2, technical name FINLAY-FR-2, is a COVID-19 vaccine produced by the Finlay Institute, a Cuban epidemiological research institute.

Which vaccine is ChAdOx1?

Introduction – As the COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continues to unfold, there has been widespread impact on health, including substantial mortality among older adults and those with pre-existing health conditions, 1, 2 and repercussions for the global economy, caused by physical distancing measures, with the greatest consequences for the most vulnerable in society.

Despite global spread of the virus, a large proportion of the population in many countries is thought to have thus far escaped infection and remains non-immune to SARS-CoV-2.3 Vaccines could play an important role in increasing population immunity, preventing severe disease, and reducing the ongoing health crisis.

In response, rapid global efforts to develop and test vaccines against SARS-CoV-2 have led to an unprecedented number of candidate vaccines starting clinical trials during 2020. Currently, 48 vaccines are under clinical evaluation.4 Several of these have shown good safety and immunogenicity, and 11 of these are currently being evaluated in phase 3 clinical efficacy studies.

The ChAdOx1 nCoV-19 vaccine (AZD1222) was developed at Oxford University and consists of a replication-deficient chimpanzee adenoviral vector ChAdOx1, containing the SARS-CoV-2 structural surface glycoprotein antigen (spike protein; nCoV-19) gene. Following initiation of a phase 1 clinical trial in the UK (COV001) on April 23, 2020, three further randomised controlled trials of the candidate vaccine were initiated across the UK (COV002), Brazil (COV003), and South Africa (COV005).

A further phase 1/2 trial has recently been initiated in Kenya and is not reported here. The immunogenicity results from the phase 1/2 UK study, COV001, in 1077 healthy adults aged 18–55 years, 5 and a phase 2 cohort in COV002 in older adults (≥56 years) 6 have been published and show an acceptable safety profile for the vaccine with induction of binding and neutralising antibodies as well as generation of interferon-γ enzyme-linked immunospot responses, with higher antibody titres after a second dose of vaccine.5, 6, 7 The phase 1 study (COV001) included an efficacy cohort and the phase 2 and 3 studies (COV002, COV003, and COV005) expanded enrolment to a wider population of participants with higher likelihood of exposure to the virus, such as health-care workers.

Is vaccines journal peer reviewed?

Journal Description – Vaccines is an international,, open access journal published monthly online by MDPI. is affiliated with Vaccines and their members receive a discount on the article processing charges.

— free for readers, with paid by authors or their institutions. High Visibility: indexed within,,,,,, and, Journal Rank: JCR – Q1 ( Immunology ) / CiteScore – Q1 ( Pharmacology (medical) ) Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 17.6 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2023). Recognition of Reviewers: reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.

Impact Factor: 7.8 (2022); 5-Year Impact Factor: 7.4 (2022)

Is barekat vaccine approved?

Authorizations – The vaccine received its authorization license from the Iran Food and Drug Administration on June 13, 2021. CovIran Barkat is in the process to be registered by the World Health Organization, Presubmission meeting held on 26 January 2022.

Jack Gloop